Journal Article

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Simony-Lafontaine, Joëlle, Turtoi, Andrei, Boissière-Michot, Florence, Chardès, Thierry, Alcaraz, Lindsay B., Bourquard, Thomas, Pirot, Nelly, Navarro-Teulon, Isabelle, Bonnefoy, Nathalie, Pugnière, Martine, Pèlegrin, André, Roger, Pascal, Derocq, Danielle, Theillet, Charles, Delpech, Helène, Bernex, Florence, Pouget, Jean-Pierre, Laurent-Matha, Valérie, Guiu, Séverine, Jacot, William, Jarlier, Marta, Poupon, Anne, Martineau, Pierre, Ashraf, Yahya, Puel, Anthony, Achour, Oussama, Mansouri, Hanane, Fruitier-Arnaudin, Ingrid, Deshayes, Emmanuel, Pichard, Alexandre, Landomiel, Flavie, Liaudet-Coopman, Emmanuelle, Robin, Gautier, Martin, Lucie, du Manoir, Stanislas, Michaud, Henri-Alexandre, Robert, Bruno

2019

Overview

Background Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC. Methods Cath-D prognostic value and localization was evaluated by transcriptomics, proteomics and immunohistochemistry in TNBC. First-in-class anti-cath-D human scFv fragments binding to both human and mouse cath-D were generated using phage display and cloned in the human IgG1 λ format (F1 and E2). Anti-cath-D antibody biodistribution, antitumor efficacy and in vivo underlying mechanisms were investigated in TNBC MDA-MB-231 tumor xenografts in nude mice. Antitumor effect was further assessed in TNBC patient-derived xenografts (PDXs). Results High CTSD mRNA levels correlated with shorter recurrence-free survival in TNBC, and extracellular cath-D was detected in the tumor microenvironment, but not in matched normal breast stroma. Anti-cath-D F1 and E2 antibodies accumulated in TNBC MDA-MB-231 tumor xenografts, inhibited tumor growth and improved mice survival without apparent toxicity. The Fc function of F1, the best antibody candidate, was essential for maximal tumor inhibition in the MDA-MB-231 model. Mechanistically, F1 antitumor response was triggered through natural killer cell activation via IL-15 upregulation, associated with granzyme B and perforin production, and the release of antitumor IFNγ cytokine. The F1 antibody also prevented the tumor recruitment of immunosuppressive tumor-associated macrophages M2 and myeloid-derived suppressor cells, a specific effect associated with a less immunosuppressive tumor microenvironment highlighted by TGFβ decrease. Finally, the antibody F1 inhibited tumor growth of two TNBC PDXs, isolated from patients resistant or not to neo-adjuvant chemotherapy. Conclusion Cath-D is a tumor-specific extracellular target in TNBC suitable for antibody-based therapy. Immunomodulatory antibody-based strategy against cath-D is a promising immunotherapy to treat patients with TNBC.

• Publisher: BioMed Central,BioMed Central Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Adjuvant chemotherapy / Animals / Antibodies / Antibodies, Monoclonal - pharmacokinetics / Antibodies, Monoclonal - therapeutic use / Antineoplastic Agents, Immunological - pharmacokinetics / Antineoplastic Agents, Immunological - therapeutic use / Basic Tumor Immunology / Biochemistry / Biochemistry, Molecular Biology / Bioengineering / Biotechnology / Breast cancer / Cancer / Cancer patients / Cancer research / Cancer therapies / Cancer treatment / Care and treatment / Cathepsin D - antagonists & inhibitors / Cathepsin D - genetics / Cathepsin D - immunology / Cell Behavior / Cell growth / Cell Line, Tumor / Cellular Biology / Chemotherapy / Cloning / Diagnosis / Displays (Marketing) / Female / Fibroblasts / Human antibody-based therapy / Humans / Immunoglobulin G / Immunohistochemistry / Immunology / Immunomodulation / Immunotherapy / Killer cells / Life Sciences / Macrophages / Medical prognosis / Medical research / Medicine / Medicine & Public Health / Messenger RNA / Mice, Nude / Oncology / Patients / Phage display / Protease / Proteases / Proteins / Proteomics / Research Article / RNA / RNA, Messenger - metabolism / TNBC / Toxicity / Transforming growth factors / Triple Negative Breast Neoplasms - drug therapy / Triple Negative Breast Neoplasms - immunology / Triple Negative Breast Neoplasms - metabolism / Triple Negative Breast Neoplasms - pathology / Tumor Burden - drug effects / Tumor microenvironment / Tumors / Xenograft Model Antitumor Assays